Atherothrombotic disease is the leading cause of morbidity and mortality; therefore, anti-thrombotic agents play a pivotal role in primary and secondary prevention of atherothrombotic complications. In "A Clinical Guide to the Use of Antithrombotic Drugs," three main sections in the field have been elaborated. In the first, 3 chapters on basics concepts of atherothrombosis are examined. The objectives of these chapters are to provide pathophysiological concepts on atherothrombosis useful to the practicing clinician to understand the rationale for using antithrombotic agents in daily practice. In the second section, 16 chapters describe 4 main categories of antithombotic agents used in clinical practice: oral antiplatelet agents, intravenous antiplatelet agents, thrombin inhibitors, and fibrinolytics. In each category, description and clinical application of currently approved agents as well as agents under clinical investigation are described. The objectives of this section are to provide the stateof the art knowledge on antithrombotic drug use and development. In the third section, a series of 8 chapters examines the application of antithrombotic agents in specific clinical scenarios. The objective of this section is to provide practical insights on how to apply antithrombotic agents in the context of daily clinical scenarios. Overall, this compendium provides a valuable tool for clinicians in their daily clinical practice on how to use currently available antithrombotic agents as well as provide insights on the future development in this field.

This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.